Biosimilars: A Chance for Breaking Biologics Cost

In recent years, in comparison with chemical drugs, the use of biologic drugs has absorbed more attention, but they are expensive for patients. Besides, many of them are approaching their patent's time of expiration, and this matter has provided the opportunity of investing in biosimilars market which leads to taking place of reference drugs with lower costs. Nevertheless, entering the biosilmilar market and starting to produce has specified problems and needs to be approved in terms of purity, efficacy and safety in the defined framework by organizations such as food and drug administration (FDA). In this research, biosimilars market is investigated according to available statistics in USA and Europe, and the production of these products in Iran is also stated.